Zynex (OTCMKTS:ZYXI) Lifted to Buy at B. Riley
B. Riley upgraded shares of Zynex (OTCMKTS:ZYXI) from a neutral rating to a buy rating in a report published on Wednesday morning, The Fly reports. B. Riley currently has $28.00 price target on the stock.
Several other equities research analysts also recently commented on the company. Northland Securities restated a hold rating and set a $22.50 price objective on shares of Zynex in a report on Wednesday. Piper Sandler started coverage on Zynex in a research report on Monday, July 20th. They set an overweight rating and a $30.00 price objective on the stock. HC Wainwright reduced their price target on Zynex from $30.00 to $25.00 and set a neutral rating on the stock in a research report on Wednesday. Finally, Zacks Investment Research upgraded Zynex from a hold rating to a buy rating and set a $12.00 target price for the company in a research note on Tuesday, March 31st. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Zynex has an average rating of Buy and a consensus target price of $23.50.
OTCMKTS ZYXI opened at $19.12 on Wednesday. The stock has a 50 day moving average of $23.36 and a 200-day moving average of $16.05. Zynex has a 12 month low of $7.51 and a 12 month high of $29.73. The company has a market cap of $663.58 million, a PE ratio of 86.91 and a beta of 1.05.
In other Zynex news, CEO Thomas Sandgaard sold 1,250,000 shares of the company’s stock in a transaction dated Tuesday, July 14th. The shares were sold at an average price of $22.00, for a total transaction of $27,500,000.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Daniel J. Moorhead purchased 2,733 shares of the stock in a transaction dated Thursday, July 30th. The stock was acquired at an average price of $18.11 per share, for a total transaction of $49,494.63. Following the completion of the transaction, the chief financial officer now directly owns 19,001 shares of the company’s stock, valued at $344,108.11. The disclosure for this purchase can be found here.
A number of large investors have recently bought and sold shares of ZYXI. Citigroup Inc. grew its holdings in Zynex by 310.6% during the 4th quarter. Citigroup Inc. now owns 3,170 shares of the company’s stock valued at $25,000 after purchasing an additional 2,398 shares in the last quarter. BNP Paribas Arbitrage SA lifted its position in Zynex by 121.9% in the 1st quarter. BNP Paribas Arbitrage SA now owns 4,866 shares of the company’s stock valued at $54,000 after purchasing an additional 2,673 shares during the last quarter. Winslow Evans & Crocker Inc. bought a new stake in Zynex in the 2nd quarter valued at about $107,000. Cubist Systematic Strategies LLC bought a new stake in Zynex in the 4th quarter valued at about $111,000. Finally, Federated Hermes Inc. bought a new stake in shares of Zynex during the 1st quarter worth about $117,000. 0.05% of the stock is currently owned by institutional investors.
Zynex Company Profile
Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.
Featured Article: Trading Ex-Dividend
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.